Program
AMT-676
A development code.
Its studies are mostly in Colorectal Neoplasms, led by Multitude Therapeutics.
Furthest: phase 2, since Mar 5, 20262 company-led studies, 2 open or runningNext primary completion: May 15, 2027 (early phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Multitude Therapeutics | 22 open or running | phase 2since Mar 5, 2026 | May 1, 2024 | May 15, 2027early phase 1 · NCT06400485 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 1, 2024First study: early phase 1 study in Advanced Solid TumorsFirst studyNCT06400485 · 24 planned · American Samoa, Australia, China
- Mar 5, 2026Phase 2 study in Colorectal NeoplasmsPhase 2 reachedNCT07474727 · 180 planned · China
Ahead
- May 15, 2027Primary completion: early phase 1 study in Advanced Solid TumorsNCT06400485
- Sep 30, 2027Primary completion: phase 2 study in Colorectal NeoplasmsNCT07474727
TargetBeta
CDH17 →read by rule
“First-in-Human, Phase I/II Study of AMT-676, an Anti CDH17 Antibody-Drug Conjugate, in Patients With Advanced Solid Tumors”study text, by rule · the study
Other programs on CDH17
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-CDH17 Antibody-drug Conjugate HS-20110 | Hansoh Pharmaceutical Group | phase 2 | 2 |
| Anti-CDH17/MF-6 Antibody-drug Conjugate 7MW4911rule | Mabwell (Shanghai) Bioscience | phase 2 | 2 |
| Anti-CDH17/Topoisomerase I Inhibitor Antibody-drug Conjugate DB-1324rule | dualitybio-inc | phase 2 | 1 |
| LM-350 | Sino Biopharmaceutical | phase 2 | 1 |
| Anti-CDH17 Antibody-drug Conjugate YL217rule | MediLink Therapeutics (Suzhou) | phase 1 | 1 |
| Anti-CDH17/Exatecan Antibody-drug Conjugate ARR-217rule | arrivent-biopharma-inc | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07474727Colorectal Neoplasms · China | 2 | Recruiting | Sep 30, 2027 | 180 |
| NCT06400485Advanced Solid Tumors · American Samoa, Australia, China | Early 1 | Recruiting | May 15, 2027 | 24 |
How it is read
Names in the registry
- “AMT-676”, 2 entries
Codes read as this program: AMT676.
Conditions, from the studies’ own filings
- Colorectal Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.